Company news
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) news
Vanda Pharmaceuticals Inc. news releases on 6ix. Latest, Oct 2, 2026: Vanda Pharmaceuticals Announces Presentation at 2026 EADV Annual Meeting
Press releases & updates
Vanda Pharmaceuticals Announces Presentation at 2026 EADV Annual Meeting
October 2, 2026
Vanda Pharmaceuticals Announces Presentation at 2026 EADV Annual Meeting
October 1, 2026
Vanda Pharmaceuticals Announces Positive Phase III Results for HETLIOZ®(tasimelteon) in Delayed Sleep-Wake Phase Disorder
September 29, 2026
Vanda Pharmaceuticals Announces Positive Phase III Results for HETLIOZ®(tasimelteon) in Delayed Sleep-Wake Phase Disorder
September 28, 2026
Vanda Pharmaceuticals Announces Participation at September 2026 Investor Conferences
September 2, 2026
Vanda Pharmaceuticals Granted Orphan Designation for Imsidolimab for the Treatment of Generalized Pustular Psoriasis by the European Commission
August 24, 2026
NEREUS™ Sponsored No. 47 IndyCar Ready for Historic Freedom 250 Grand Prix in Washington, D.C.
August 22, 2026
Vanda Pharmaceuticals Reports Second Quarter 2026 Financial Results
August 5, 2026
Vanda Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 5, 2026
July 29, 2026
Vanda Pharmaceuticals Announces EMA Positive Opinion for Orphan Drug Designation of Imsidolimab for Generalized Pustular Psoriasis - A Milestone Recognition of GPP as a Distinct Rare Disease in Europe
July 16, 2026
NEREUS™ Powers Forward: Sponsors No. 47 IndyCar Entry, Celebrating 47 Years Since Last New U.S. Motion Sickness Treatment
July 15, 2026
Vanda Pharmaceuticals Announces Participation in the B. Riley Securities 2026 Mind, Muscle & Vision Summit
July 10, 2026
Vanda Pharmaceuticals Announces FDA Rare Pediatric Disease Designation for Investigational Therapy for Charcot-Marie-Tooth Disease Type 2S
July 7, 2026
Vanda Pharmaceuticals Announces Orphan Drug Designation in Japan for Imsidolimab in Generalized Pustular Psoriasis
May 26, 2026
Vanda Pharmaceuticals Announces Participation at May 2026 Investor Conferences
May 7, 2026
Vanda Pharmaceuticals Reports First Quarter 2026 Financial Results
May 5, 2026
Model N Appoints Thomas Gibbs to Board of Directors
May 5, 2026
Vanda Pharmaceuticals Announces U.S. Commercial Availability of NEREUS™ (tradipitant), the First New Pharmacologic Treatment for People with Motion Sickness in More Than 40 Years
May 1, 2026
Vanda Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026
April 29, 2026
Vanda Pharmaceuticals announces the publication of "Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis" in NEJM Evidence
April 28, 2026
Vanda Pharmaceuticals Appoints Dr. Charles Duncan to its Board of Directors
April 22, 2026
Vanda Pharmaceuticals Calls on FDA to Withdraw Proposal from FY 2027 Legislative Agenda That Would Extend Drug Review Timelines
April 9, 2026
Vanda Pharmaceuticals Announces Initiation of The Thetis Study, a Clinical Trial of NEREUS™ for the Prevention of Vomiting Induced by GLP-1 Receptor Agonists
April 7, 2026
Vanda Pharmaceuticals Calls for Stronger FDA Action to Accelerate Shift from Animal Testing to Human-Relevant Methods
March 19, 2026
Vanda Announces FDA Grants Landmark Hearing for HETLIOZ® in Jet Lag Disorder, the First Drug Approval Hearing in Over 40 Years
March 2, 2026
Vanda Pharmaceuticals Announces Participation in the 2026 Citizens Life Sciences Conference
February 26, 2026
Vanda Pharmaceuticals Announces FDA Acceptance of Biologics License Application Filing for Imsidolimab for the Treatment of Generalized Pustular Psoriasis
February 25, 2026
Vanda Pharmaceuticals Announces FDA Approval of BYSANTI™ (milsaperidone) for the treatment of Bipolar I Disorder and Schizophrenia - A New Chemical Entity Opening New Horizons in Psychiatric Innovation
February 19, 2026
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results
February 11, 2026
Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026
February 4, 2026
Vanda Pharmaceuticals Announces Receipt of FDA Decision Letter on HETLIOZ® Supplemental New Drug Application for Jet Lag Disorder
January 7, 2026
Vanda Pharmaceuticals Announces FDA Approval of NEREUS™ (tradipitant) for the Prevention of Vomiting Induced by Motion: A Historic Scientific Milestone in the Prevention of Motion Sickness
December 29, 2025
Vanda Announces Submission of Biologics License Application to the FDA for Imsidolimab for the Treatment of Generalized Pustular Psoriasis
December 14, 2025
Vanda Pharmaceuticals Announces Participation in the J.P. Morgan Healthcare Conference
December 10, 2025
FDA Lifts Partial Clinical Hold on Tradipitant for Motion Sickness
December 3, 2025
Vanda Pharmaceuticals Provides Regulatory Update on Tradipitant for Motion Sickness
November 27, 2025
Vanda Pharmaceuticals Reports Positive Results for Tradipitant in Preventing GLP-1 Induced Nausea and Vomiting
November 16, 2025
Vanda Pharmaceuticals Announces Participation in the Stifel 2025 Healthcare Conference
November 4, 2025
Vanda Pharmaceuticals Reports Third Quarter 2025 Financial Results
October 28, 2025
Vanda Pharmaceuticals to Announce Third Quarter 2025 Financial Results on October 29, 2025
October 21, 2025
Monumental Sports & Entertainment Taps D.C.'s Own Vanda Pharmaceuticals as Founding Partner to Help Drive the Creation of Brand-New Downtown Arena
October 8, 2025
Vanda Pharmaceuticals Announces Collaborative Framework for Resolution of Disputes with the U.S. Food and Drug Administration
September 30, 2025
Vanda Pharmaceuticals announces the publication in PLOS One of an article titled "Melatonin agonist tasimelteon (HETLIOZ®) improves sleep in patients with primary insomnia: A multicenter, randomized, double-blind, placebo-controlled trial"
September 24, 2025
Vanda Pharmaceuticals Announces Participation at September 2025 Investor Conferences
August 27, 2025
Vanda Pharmaceuticals Announces FDA Granted Orphan Drug Designation for VGT-1849B, a Novel and Selective Candidate for the Treatment of Polycythemia Vera
August 27, 2025
Vanda Seeks FDA Commissioner Review of Outgoing CDER Director's Decision to Uphold Approval of Two Generic Versions of Hetlioz®
August 20, 2025
In a Major Win for Vanda, a Federal Appeals Court Overturns FDA's Order Denying Approval of Hetlioz for the Treatment of Jet Lag Disorder
August 17, 2025
Vanda Pharmaceuticals Reports Second Quarter 2025 Financial Results
July 30, 2025
Vanda Pharmaceuticals to Announce Second Quarter 2025 Financial Results on July 31, 2025
July 22, 2025
Vanda Pharmaceuticals Announces First Patient Dosed in a Trial Evaluating VCA-894A in Charcot-Marie-Tooth disease Type 2S
June 9, 2025